Summit Therapeutics stock
SMMTNASDAQSummit Therapeutics Inc., HealthcareISIN US86627T1088
34Score 34 out of 100, Weak
Price and trend
60 / 100
Price history
−20% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.7% below it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 43% below its 52-week high. Largest decline in 12 years: 96% (September 2017 to December 2022).
Chart figures for advanced users
- SMA 50$16.47
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.15
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$12.43
- The lowest closing price of the last twelve months.
- Resistance$26.38
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Summit Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $12.03B, is number 29 of 289 companies in its industry on MEQIRI.
- MEQIRI Score 34 out of 100 (Weak): rank 636 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $713.45M, financial debt $20.89M.Stability 69
Weaknesses
- Loss-makingLoss of $1.08B over the last 12 months.Fundamentals 20
- Negative free cash flowFree cash flow −$323.59M over the last 12 months.Fundamentals 20
- Volatile share priceVolatility 75% a year over the last 12 months.Stability 69
The score is held back by fundamentals and profitability.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 39 to 34.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2008 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. From 2008 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 22 Feb 2027in 101 days
- Last reported
- 4 Nov 2026EPS reported −$0.26 (expected −$0.28)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 10.7% since 15 Oct 2026.
- Earnings per share
- −$1.05+9.3%
- Revenue
- $2.5M−31.6%
- Earnings per share
- −$1.01+10.7%
- Revenue
- $59.23M−0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −7.3%Trial timelines as previously guided: progression free survival data for the squamous cohort in the second half of 2026 and for the non-squamous cohort in the first half of 2027.
“For the non-squamous cohort, we expect to reach the number of events needed to conduct a progression-free survival analysis in the first half of 2027.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $52.17M in total.
- Duggan Robert W, Zanganeh MahkamPurchase
12 Jun 2026, 10 percent owner, officer: Co-Chief Executive Officer
- Shares
- 3,810,000
- Price
- $13.12
- Value
- $49.99M
- Duggan Robert W, Zanganeh MahkamPurchase
4 Jun 2026, 10 percent owner, officer: Co-Chief Executive Officer
- Shares
- 100,000
- Price
- $14.60
- Value
- $1.46M
- Soni Manmeet SinghPurchase
4 Jun 2026, COO and CFO
- Shares
- 50,000
- Price
- $14.45
- Value
- $722,250
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Summit Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 702 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.9B49
- Kymera TherapeuticsKYMR $12.73B45
- Madrigal PharmaceuticalsMDGL $12.44B33
- Pharmaron Beijing300759.SZ $12.15B58
- Financière de TubizeTUB.BR $11.94B50
- Halozyme TherapeuticsHALO $11.48B80
- Bio-TechneTECH $11.44B64
- BioMarin PharmaceuticalBMRN $10.98B48
ETFs that hold Summit Therapeutics
Held by 7 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.74% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.41% | 0.25% | €45.16M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.54B |
Show 3 more
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €178.55M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2020)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.